Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446056 | 1.00 | HTT (0.66) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL38657150 | 0.85 | TDP1 (0.64) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL1027041 | 0.85 | TDP1 (0.64) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL527567 | 0.82 | HTT (0.72) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL29441283 | 0.82 | HTT (0.72) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL12782259 | 0.81 | MAPT (0.51) | HTTTDP1LMNAPTGS2CYP19A1 | |
| SCHEMBL5652275 | 0.80 | RECQL (0.51) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL57125 | 0.79 | HTT (0.68) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL222283 | 0.79 | HTT (1.00) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL8977874 | 0.79 | HTT (0.68) | HTTTDP1PKMLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2024177984-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | HTT 2982/4885TDP1 1176/4885PKM 841/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | HTT 2982/4885TDP1 1176/4885PKM 841/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | HTT 2982/4885TDP1 1176/4885PKM 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.